TABLE 1

Randomised phase III trials comparing tyrosine kinase inhibitors with best supportive care as salvage therapy

First author [ref.]Treatment armPatients nObjective response %p-valueMedian survival monthsp-value
Shepherd [2]Erlotinib4888.9<0.0016.7<0.001
Placebo24314.7
Thatcher [3]Gefitinib11298<0.00015.60.09
Placebo5631.35.1